Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Name: Kaimen Rigor review — Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.
Item: Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.
Rating: 100
Author: Alpha1

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

Read full text (PMC)

DOI

10.1038/s41591-025-03556-3

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/261ca55e-e170-4222-a819-fc98c2c15307" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/261ca55e-e170-4222-a819-fc98c2c15307/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

13a9a9d4ad7ced6e0839d1cf65b71a8d033fc74639d3f2af1f7bacc76a6e09fe

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

Paper source

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on weight loss percentage, which is a surrogate endpoint for clinical outcomes such as cardiovascular morbidity and mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this specific context.
“The primary outcome was met; early nonresponders assigned to BT + AOM had a greater mean (±s.e.) reduction in weight of 5.9 ± 0.7% from randomization to week 24, as compared to 2.8 ± 0.7% for those assigned to BT + P”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is a 3.1 percentage point difference in weight loss between groups, which is statistically significant but not anchored to a minimal clinically important difference or a clear biological/clinical meaningfulness threshold. The paper mentions that a ≥5% weight loss is clinically meaningful, but the between-group difference is below this threshold.
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported double-blind RCT evaluating phentermine added to behavioral treatment in early nonresponders. The study design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria. Minor reporting inconsistencies (e.g., Cohen's d discrepancy) and a few clarity issues are present but do not undermine the overall integrity.

Both reviewers classified the study as interventional (RCT), and this was adopted. The evaluation covered the full text, with all eight dimensions applicable. Not-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 3 tests; other reported statistics were not machine-verified and should not be assumed correct.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple studies on behavioral treatment, early nonresponse, and anti-obesity medications, and clearly identifies the gap: no randomized trial has tested adding AOM to BT in early nonresponders. The rationale is well-articulated, and the study directly addresses this gap. Limitations of prior work are acknowledged, such as the lack of studies on rapid step-up approaches.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶1Find in source

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Several studies have examined the efficacy of stepped-care approaches for obesity treatment... To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

“The baseline treatment offered in these programs has typically been of low intensity... and treatment has primarily been intensified by increasing provider contact rather than by offering an adjunctive intervention.”

The trial is described as double-blind, randomized, with permuted blocks and random number tables. Blinding is stated (double-blind). A priori power calculation is provided. Inclusion/exclusion criteria are detailed. The analysis population (ITT) and missing data handling (mixed models, multiple imputation) are described. The study is a single-center RCT, and independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous with clear randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization]

“early nonresponders—who lost <2.0% of baseline weight—were randomly assigned 1:1 to the AOM phentermine (15 mg d−1) or placebo in permuted blocks of 2–4 participants via random number tables.”

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

PASSReviewer 2· 90% conf

The RCT design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria.

Evidence

paraphrase[Methods, Randomization]

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

The paper reports sex (predominantly female), age, weight, BMI, and race/ethnicity for the run-in cohort and the randomized groups. Since both sexes are enrolled, sex_justified is not applicable. Health status is partially reported via exclusion criteria and baseline characteristics. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, BMI, and race/ethnicity.

Evidence

paraphrase[Results, Phase 1]

“The 147 participants who passed the screening and enrolled in the 4-week BT run-in were predominantly female (87.1%, n = 128); 80 (54.5%) self-identified as white, 57 (38.8%) as Black and 5 (3.4%) as Asian; 7 (4.8%) identified as Hispanic. Participants had a mean baseline age of 48.5 years (s.d. = 12.4), weight of 104.6 kg (s.d. = 19.8) and BMI of 37.7 kg m−2 (s.d. = 6.4”

“Sex (female), n (%) | 66 (86.8%) | 30 (78.9%) | 36 (94.7%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported for this human trial.

Evidence

ResultsFind in source

paraphrase[Results, Phase 1]

“Participants had a mean baseline age of 48.5 years (s.d. = 12.4), weight of 104.6 kg (s.d. = 19.8) and BMI of 37.7 kg m−2 (s.d. = 6.4”

The study was approved by the University of Pennsylvania IRB, and written informed consent was obtained. Compliance with ethical standards is implied through IRB approval and trial registration.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval and informed consent are clearly documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

Phentermine is identified by name, dose, and manufacturer (not explicitly, but the drug is well-known). The study uses a digital scale (Tanita, BWB800) and home scales (EatSmart, ESBS-01). Statistical software (SPSS, R) is identified. No antibodies, cell lines, or other biological reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (phentermine) is adequately identified, and software tools are named.

Evidence

paraphrase[Abstract and Methods]

“BT plus AOM (phentermine = 15.0 mg d−1, n = 38)”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (phentermine) and software are adequately identified.

Evidence

paraphrase[Methods, Phase 2]

“Phentermine was provided as 8.0 mg d−1 for the first 2 weeks to facilitate its acceptance. The dose was then increased at week 2–15 mg d−1”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

The primary analysis uses mixed-effects models, which are appropriate for repeated measures. Tests are named (mixed-effects models, chi-square). Exact p-values are reported (e.g., P = 0.003). Effect sizes with confidence intervals are provided (e.g., mean difference = 3.1 ± 1.0, 95% CI = 1.1–5.1%). Software is identified. Data presentation includes individual data points in waterfall plots and error bars defined. Mathematical plausibility checks were not performed due to continuous outcomes and model-derived estimates.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%”

AbstractFind in source

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Mean percentage reductions in initial weight in the intention-to-treat population were compared using mixed-effects models”

Statistical analysisFind in source

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73”

AbstractFind in source

The data availability statement provides a clear mechanism for accessing de-identified data through a review process and data-sharing agreement. It explains why data cannot be freely available due to privacy. Code availability states that no custom code was generated, and standard software was used. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, and code availability is addressed.

Evidence

“Data will be provided following the review and approval of a research proposal (including a statistical analysis plan) by the corresponding author and at least one other doctoral-level researcher at the University of Pennsylvania.”

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly described with a managed-access procedure, and code is not applicable.

Evidence

“De-identified participant data used in the present analyses will be made available to investigators for research purposes after release of this publication. Data will be provided following the review and approval of a research proposal (including a statistical analysis plan) by the corresponding author and at least one other doctoral-level researcher at the University of Pennsylvania. The initial review will be completed within 3 months of receipt of the proposal.”

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

The trial is registered (NCT03779048). A CONSORT 2010 checklist is mentioned in supplementary information. All outcomes are reported, including secondary and exploratory. Limitations are discussed in detail. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, CONSORT checklist, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

“The primary limitation of this study was the relatively small sample of randomized participants, which was not adequately powered to detect group differences in outcomes other than percent reduction in body weight.”

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

Reporting is complete with trial registration, CONSORT checklist, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

Discussion ¶7Find in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 36 references by DOI: 2 verified — 34 no DOI (shown, not verified).

2 of 3 data/code links checked; 2 live; 1 not probed.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor inconsistencies (Cohen's d discrepancy, terminology ambiguity) and the small sample size as limitations, but these do not warrant a correction. The data availability statement is adequate, and no integrity concerns were raised.

1.
HIGHcopyedit
Reconcile the Cohen's d value for the primary outcome between the Abstract (0.73) and Table 2 (0.72) to ensure consistency.
An internal inconsistency in a reported effect size could confuse readers and undermine trust in the reported results.
2.
HIGHcopyedit
Clarify the term 'nonresponders' in the Results section (Phase 2) where it refers to participants with missing vitals, to avoid ambiguity with early nonresponders.
Ambiguous terminology could mislead readers about which participant subgroup is being described.
3.
MEDIUMreporting
Clarify the sentence in Methods, Statistical analyses about missing data in mixed-effects models to explicitly state how missing data are handled for the primary outcome.
The current wording is confusing and could be misinterpreted regarding the analysis population.
4.
MEDIUMreporting
Consider reporting the exact p-value for the secondary outcome of ≥10% weight loss (currently reported as P = 0.078) to enhance precision.
Exact p-values are preferred over threshold reporting for transparency and reproducibility.
5.
MEDIUMreporting
Consider reporting the exact p-value for the exploratory comparison between early responders and BT+AOM (currently reported as not significant without a value).
Providing exact p-values for all reported comparisons improves completeness.
6.
MEDIUMdata code
Consider specifying the exact data-sharing agreement terms or providing a link to the protocol repository in the Data Availability statement.
More specific access details would facilitate data reuse and enhance transparency.
7.
MEDIUMreporting
Consider adding a statement about the handling of missing data for the primary outcome in the CONSORT flow diagram to improve transparency.
Clear reporting of missing data handling is essential for assessing potential bias.
8.
MEDIUMreporting
Consider reporting the intraclass correlation or variance components from the mixed models to aid replication.
Providing model parameters would allow others to replicate the analysis more accurately.
9.
MEDIUMreporting
Consider providing the full statistical analysis plan as a supplementary file to strengthen reproducibility.
A full SAP would enhance transparency and allow verification of pre-specified analyses.
10.
MEDIUMreporting
Consider reporting the number of participants who discontinued treatment and the reasons in a more detailed table.
Detailed discontinuation information is important for assessing attrition bias.
11.
MEDIUMrigor
Consider adding a sensitivity analysis excluding participants with remote weight measurements to assess robustness.
Remote measurements may introduce measurement variability; a sensitivity analysis would strengthen the conclusions.
12.
LOWreporting
Consider reporting the manufacturer and lot number for phentermine and placebo in the Methods to fully satisfy resource identification.
Providing product details enhances reproducibility and resource identification.
13.
LOWreporting
Consider providing a more detailed description of the randomization sequence generation and allocation concealment in the Methods.
More detail on randomization procedures would further strengthen the design description.
14.
LOWethics
Consider adding a statement about adherence to the Declaration of Helsinki or other ethical guidelines in the Methods.
Explicitly stating adherence to ethical guidelines is a good practice for human research.
15.
LOWcopyedit
Rephrase the sentence in Discussion, paragraph 3 for grammatical clarity: '...if they are provided with adjunctive AOM at that time.'
Minor grammatical improvement enhances readability.

Full text (65,150 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.

Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA

Read full text (PMC)

DOI

10.1038/s41591-025-03556-3

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/261ca55e-e170-4222-a819-fc98c2c15307" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/261ca55e-e170-4222-a819-fc98c2c15307/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

13a9a9d4ad7ced6e0839d1cf65b71a8d033fc74639d3f2af1f7bacc76a6e09fe

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on weight loss percentage, which is a surrogate endpoint for clinical outcomes such as cardiovascular morbidity and mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking weight loss to hard clinical outcomes in this specific context.
“The primary outcome was met; early nonresponders assigned to BT + AOM had a greater mean (±s.e.) reduction in weight of 5.9 ± 0.7% from randomization to week 24, as compared to 2.8 ± 0.7% for those assigned to BT + P”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size is a 3.1 percentage point difference in weight loss between groups, which is statistically significant but not anchored to a minimal clinically important difference or a clear biological/clinical meaningfulness threshold. The paper mentions that a ≥5% weight loss is clinically meaningful, but the between-group difference is below this threshold.
“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73, P = 0.003”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶1Find in source

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

“To our knowledge, no studies have investigated whether a rapid step-up approach improves weight loss in early nonresponders who are already receiving 6 months of intensive BT.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Remarkably, the recommendation to offer AOM to individuals who are unable to successfully lose weight with BT alone has never been tested in a randomized trial.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 3]

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous with clear randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization]

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

PASSReviewer 2· 90% conf

The RCT design is rigorous with adequate randomization, blinding, power analysis, and pre-specified criteria.

Evidence

paraphrase[Methods, Randomization]

“was a single-center, double-blinded, parallel-group design randomized controlled trial”

MethodsFind in source

“a randomized sample of 50 nonresponders (25 per group) was expected to provide 81.5% power to detect between-group differences at week 24 in the primary outcome (two-tailed α level = 0.05).”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, weight, BMI, and race/ethnicity.

Evidence

paraphrase[Results, Phase 1]

“Sex (female), n (%) | 66 (86.8%) | 30 (78.9%) | 36 (94.7%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported for this human trial.

Evidence

ResultsFind in source

paraphrase[Results, Phase 1]

“Participants had a mean baseline age of 48.5 years (s.d. = 12.4), weight of 104.6 kg (s.d. = 19.8) and BMI of 37.7 kg m−2 (s.d. = 6.4”

The study was approved by the University of Pennsylvania IRB, and written informed consent was obtained. Compliance with ethical standards is implied through IRB approval and trial registration.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval and informed consent are clearly documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately documented.

Evidence

“conducted at the University of Pennsylvania, whose institutional review board approved the study protocol”

MethodsFind in source

“who obtained written informed consent and assessed applicants’ behavioral and psychological eligibility.”

MethodsFind in source

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (phentermine) is adequately identified, and software tools are named.

Evidence

paraphrase[Abstract and Methods]

“BT plus AOM (phentermine = 15.0 mg d−1, n = 38)”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (phentermine) and software are adequately identified.

Evidence

paraphrase[Methods, Phase 2]

“Phentermine was provided as 8.0 mg d−1 for the first 2 weeks to facilitate its acceptance. The dose was then increased at week 2–15 mg d−1”

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%”

AbstractFind in source

“Analyses were conducted in SPSS Statistics v.28.0.1.1.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Mean percentage reductions in initial weight in the intention-to-treat population were compared using mixed-effects models”

Statistical analysisFind in source

paraphrase[Abstract]

“P = 0.003”

“mean difference = 3.1 ± 1.0, 95% confidence interval = 1.1–5.1%, Cohen’s d = 0.73”

AbstractFind in source

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is concrete, and code availability is addressed.

Evidence

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly described with a managed-access procedure, and code is not applicable.

Evidence

Data availabilityFind in source

“No custom code was generated for the present analyses.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, CONSORT checklist, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

Discussion ¶7Find in source

PASSReviewer 2· 90% conf

Reporting is complete with trial registration, CONSORT checklist, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03779048”

AbstractFind in source

“Supplementary Note (CONSORT 2010 checklist, summary of protocol modifications and full study protocol).”

Supplementary materialFind in source

Discussion ¶7Find in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 36 references by DOI: 2 verified — 34 no DOI (shown, not verified).

2 of 3 data/code links checked; 2 live; 1 not probed.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
Reconcile the Cohen's d value for the primary outcome between the Abstract (0.73) and Table 2 (0.72) to ensure consistency.
An internal inconsistency in a reported effect size could confuse readers and undermine trust in the reported results.
2.
HIGHcopyedit
Clarify the term 'nonresponders' in the Results section (Phase 2) where it refers to participants with missing vitals, to avoid ambiguity with early nonresponders.
Ambiguous terminology could mislead readers about which participant subgroup is being described.
3.
MEDIUMreporting
Clarify the sentence in Methods, Statistical analyses about missing data in mixed-effects models to explicitly state how missing data are handled for the primary outcome.
The current wording is confusing and could be misinterpreted regarding the analysis population.
4.
MEDIUMreporting
Consider reporting the exact p-value for the secondary outcome of ≥10% weight loss (currently reported as P = 0.078) to enhance precision.
Exact p-values are preferred over threshold reporting for transparency and reproducibility.
5.
MEDIUMreporting
Consider reporting the exact p-value for the exploratory comparison between early responders and BT+AOM (currently reported as not significant without a value).
Providing exact p-values for all reported comparisons improves completeness.
6.
MEDIUMdata code
Consider specifying the exact data-sharing agreement terms or providing a link to the protocol repository in the Data Availability statement.
More specific access details would facilitate data reuse and enhance transparency.
7.
MEDIUMreporting
Consider adding a statement about the handling of missing data for the primary outcome in the CONSORT flow diagram to improve transparency.
Clear reporting of missing data handling is essential for assessing potential bias.
8.
MEDIUMreporting
Consider reporting the intraclass correlation or variance components from the mixed models to aid replication.
Providing model parameters would allow others to replicate the analysis more accurately.
9.
MEDIUMreporting
Consider providing the full statistical analysis plan as a supplementary file to strengthen reproducibility.
A full SAP would enhance transparency and allow verification of pre-specified analyses.
10.
MEDIUMreporting
Consider reporting the number of participants who discontinued treatment and the reasons in a more detailed table.
Detailed discontinuation information is important for assessing attrition bias.
11.
MEDIUMrigor
Consider adding a sensitivity analysis excluding participants with remote weight measurements to assess robustness.
Remote measurements may introduce measurement variability; a sensitivity analysis would strengthen the conclusions.
12.
LOWreporting
Consider reporting the manufacturer and lot number for phentermine and placebo in the Methods to fully satisfy resource identification.
Providing product details enhances reproducibility and resource identification.
13.
LOWreporting
Consider providing a more detailed description of the randomization sequence generation and allocation concealment in the Methods.
More detail on randomization procedures would further strengthen the design description.
14.
LOWethics
Consider adding a statement about adherence to the Declaration of Helsinki or other ethical guidelines in the Methods.
Explicitly stating adherence to ethical guidelines is a good practice for human research.
15.
LOWcopyedit
Rephrase the sentence in Discussion, paragraph 3 for grammatical clarity: '...if they are provided with adjunctive AOM at that time.'
Minor grammatical improvement enhances readability.

Full text (65,150 chars)Analyzed: Aug 15, 2026